<html><body><h2>Case: 105236</h2><h3> CDS Time: 2011-05-31</h3>
<patient name=105236>
65.0 year old Hispanic Male
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">65</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">UrineProtein_12h</td><td width="200">9</td><td width="200">1965-8-26</td></tr>
<tr><td width="200">Calcium</td><td width="200">10</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">UrineProtein_24h</td><td width="200">9</td><td width="200">1965-8-26</td></tr>
<tr><td width="200">Alkaline_phosphatase</td><td width="200">154</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">Phosphorus</td><td width="200">3</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">47</td><td width="200">1965-8-26</td></tr>
<tr><td width="200">Chloride</td><td width="200">105.0</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">HDL_Cholesterol</td><td width="200">33</td><td width="200">1965-8-26</td></tr>
<tr><td width="200">Diastolic_BP</td><td width="200">50</td><td width="200">1965-8-29</td></tr>
<tr><td width="200">BNP</td><td width="200">5,824</td><td width="200">1963-7-23</td></tr>
<tr><td width="200">B 12</td><td width="200">406.0</td><td width="200">1963-7-7</td></tr>
<tr><td width="200">Weight</td><td width="200">138</td><td width="200">1965-8-29</td></tr>
<tr><td width="200">Uric_Acid</td><td width="200">7</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">HbA1C</td><td width="200">7</td><td width="200">1965-8-26</td></tr>
<tr><td width="200">Triglycerides</td><td width="200">192</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">Total_Cholesterol</td><td width="200">118</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">SGOT</td><td width="200">23</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">Systolic_BP</td><td width="200">134</td><td width="200">1965-8-29</td></tr>
<tr><td width="200">Total_Bilirubin</td><td width="200">0</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">Height</td><td width="200">65</td><td width="200">1965-7-25</td></tr>
<tr><td width="200">Potassium</td><td width="200">5</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">Cholesterol</td><td width="200">118</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">BUN</td><td width="200">52</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">HCT</td><td width="200">35</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">HGB</td><td width="200">12</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">Sodium</td><td width="200">139</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">Albumen</td><td width="200">4</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">Creatinine</td><td width="200">1.5</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">Glycosylated_Hemoglobin</td><td width="200">7</td><td width="200">1965-8-26</td></tr>
<tr><td width="200">UrineProtein_Qualitative</td><td width="200">9.0</td><td width="200">1965-8-26</td></tr>
<tr><td width="200">UrineProtein_Spot</td><td width="200">9</td><td width="200">1965-8-26</td></tr>
<tr><td width="200">Pulse</td><td width="200">61</td><td width="200">1965-8-29</td></tr>
<tr><td width="200">PLT</td><td width="200">158</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">WBC</td><td width="200">5</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">eGFR</td><td width="200">50</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">7.0</td><td width="200">1965-8-29</td></tr>
<tr><td width="200">SGPT</td><td width="200">34</td><td width="200">1965-8-27</td></tr>
<tr><td width="200">Sex</td><td width="200">Male</td><td width="200"></td></tr>
<tr><td width="200">Race</td><td width="200">Hispanic</td><td width="200"></td></tr>
<tr><td width="200">Retinopathy</td><td width="200"></td><td width="200">1965-7-19</td></tr>
<tr><td width="200">DM-Type2</td><td width="200"></td><td width="200">1965-6-18</td></tr>
<tr><td width="200">CKD</td><td width="200"></td><td width="200">1964-10-16</td></tr>
<tr><td width="200">Diabetes with renal manifestations</td><td width="200"></td><td width="200">1965-8-29</td></tr>
<tr><td width="200">Renal_Insufficiency</td><td width="200"></td><td width="200">1964-10-16</td></tr>
<tr><td width="200">Renal disease</td><td width="200"></td><td width="200">1964-10-16</td></tr>
<tr><td width="200">Prostatism_BPH</td><td width="200"></td><td width="200">1964-7-10</td></tr>
<tr><td width="200">kidney</td><td width="200"></td><td width="200">1965-6-18</td></tr>
<tr><td width="200">Hypertension</td><td width="200"></td><td width="200">1965-7-25</td></tr>
</table>
<p><b>Medications:</b> tacrolimus(6.0) aspirin(162.0) labetalol(20.0) clonidine(0.6) simvastatin(40.0) tamsulosin(1.2) lisinopril(10.0) hydralazine(30.0) rosiglitazone(4.0) furosemide(80.0) pravastatin(80.0) Insulin(1.0) 
<p><b>Problems:</b> <table>
<tr><td width="200"><b>Problem Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr><td width="200">Transplant recipients</td>
<td width="200">1965-06-18</td>
<td width="200"> kidney()</td></tr>
<tr><td width="200">Target_Organ_Damage_Clinical_Cardiovascular_Disease</td>
<td width="200"></td>
<td width="200"> TOD/CCD[presence of retinopathy]()</td></tr>
<tr><td width="200">Dyslipidemia Lab criteria</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab criteria[HDL_Cholesterol(33.0/1965-8-26)]()</td></tr>
<tr><td width="200">BPH, on one antihypertensive, no alpha blocker</td>
<td width="200"></td>
<td width="200"> BPH, on one antihypertensive, no alpha blocker[Antihypertensive_Agents && Presence of BPH && Absence of Alpha Blocker]()</td></tr>
<tr><td width="200">DM (2ary prev)  BP controlled</td>
<td width="200"></td>
<td width="200"> Diabetes (Secondary Prevention)[Treatment_Diastolic_BP(50/null) && Treatment_Systolic_BP(134/null) && presence of diabetes mellitus]()</td></tr>
<tr><td width="200">Major Cardiovascular Risk Factor</td>
<td width="200"></td>
<td width="200"> Major Cardiovascular Risk Factor[presence of diabetes mellitus]()</td></tr>
<tr><td width="200">Dyslipidemia Lab or ICD9</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab or ICD9[presence of dyslipidemia lab criteria]()</td></tr>
<tr><td width="200">CKD by eGFR</td>
<td width="200"></td>
<td width="200"> CKD by eGFR[eGFR(50.0/1965-8-27)]()</td></tr>
<tr><td width="200">CKD by eGFR or ICD9 codes</td>
<td width="200"></td>
<td width="200"> CKD[eGFR(50.0/1965-8-27)]()</td></tr>
<tr><td width="200">On meds & Presence of strong contraindication to HCTZ or using bad drug partner</td>
<td width="200"></td>
<td width="200"> Hypertension[taking furosemide && Antihypertensive_Agents]()</td></tr>
<tr><td width="200">active prescription for furosemide</td>
<td width="200"></td>
<td width="200"> active prescription for furosemide[taking furosemide]()</td></tr>
<tr><td width="200">on >= 1 med</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">taking >= 2 anti hypertensive meds</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">On 1 drug and there exists contraindicated drug or a compelling drug not given</td>
<td width="200"></td>
<td width="200"> On 1 drug and there exists contraindicated drug or a compelling drug not given[there exists a compellingly indicated drug that is not already given]()</td></tr>
<tr><td width="200">drug intolerance ACE/ARB OR hypotension OR renal insufficiency</td>
<td width="200"></td>
<td width="200"> drug intolerance ACE/ARB OR hypotension OR renal insufficiency[presence of renal insufficiency ICD9]()</td></tr>
<tr><td width="200">Absence of Stage D HF</td>
<td width="200"></td>
<td width="200"> Absence of Stage D HF[Not Stage D HF (refractory end stage HF)Stage D HF (refractory end stage HF)]()</td></tr>
<tr><td width="200">High Risk for HF and DM, HTN, or atherosclerotic vascular disease</td>
<td width="200"></td>
<td width="200"> High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus && Absence of HF]()</td></tr>
<tr><td width="200">Renal-Urinary_Diseases</td>
<td width="200">1964-10-16</td>
<td width="200"> CKD()</td></tr>
<tr> <td width="200"></td>
<td width="200">1964-07-10</td>
<td width="200"> Prostatism_BPH()</td></tr>
<tr> <td width="200"></td>
<td width="200">1964-10-16</td>
<td width="200"> Renal_Insufficiency()</td></tr>
<tr> <td width="200"></td>
<td width="200">1964-10-16</td>
<td width="200"> Renal disease()</td></tr>
<tr><td width="200">Hypertension_Inclusive</td>
<td width="200">1965-07-25</td>
<td width="200"> Hypertension()</td></tr>
<tr><td width="200">CCS-6.7</td>
<td width="200">1965-07-19</td>
<td width="200"> Retinopathy()</td></tr>
<tr><td width="200">Endocrine_Diseases</td>
<td width="200">1965-06-18</td>
<td width="200"> DM-Type2()</td></tr>
<tr> <td width="200"></td>
<td width="200">1965-08-29</td>
<td width="200"> Diabetes with renal manifestations()</td></tr>
<tr><td width="200"> <b>Others</b></td>
<td width="200"></td>
<td width="200"> Race()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Sex()
</table><p>
</patient>
<h1 align="center">ATHENA Heart Failure Guideline</h1>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)Stage D HF (refractory end stage HF))</i>]
</ul>
<b>Scenario choice:</b> Stage A HF
<b>Scenario choice:</b> Stage C HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> achieved(Treatment_Diastolic_BP(50/null) && Treatment_Systolic_BP(134/null))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> achieved(LDL_Cholesterol(47.0/1965-8-26))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</b> because <i>diabetes_mellitus</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b> </b><br>
<ul>
<li><b>stage A drug choices <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM or HTN or atherosclerotic vascular disease</i> evaluate to <b> true</b> because <i>diabetes_mellitus</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul><li>ARB<ul><li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus && Absence of HF]) <li>preference: preferred</ul><li>Ace_Inhibitor(Captopril, Lisinopril, Enalapril)<ul><li>Already being used<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus && Absence of HF]) <li>preference: ruled out</ul></ul></body></html>